Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

Giovanni Paganelli(Ripamonti), Stefania Zoboli(European Institute of Oncology), Marta Cremonesi(European Institute of Oncology), Lisa Bodei(European Institute of Oncology), Mahila Ferrari(European Institute of Oncology), Chiara Grana(Ripamonti), Mirco Bartolomei(Ripamonti), Franco Orsi(European Institute of Oncology), Concetta De Cicco(European Institute of Oncology), Helmut R. Mäcke(University Hospital of Basel), Marco Chinol(Ripamonti), Filippo de Braud(European Institute of Oncology)

European Journal of Nuclear Medicine and Molecular Imaging

April 1, 2001

10.1007/s002590100490

Cited by 205

Abstract

Related Papers

Reporting results of cancer treatment

A. B. Miller, Barth Hoogstraten, M. Staquet et al.|Cancer|1981|7.9k

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

Jean Claude Reubi, Jean-Claude Schär, Beatrice Waser et al.|European Journal of Nuclear Medicine and Molecular Imaging|2000|1.1k

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

Andreas Otte, R Herrmann, A Heppeler et al.|PubMed|1999|370

Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy

A. Heppeler, Sylvie Froidevaux, Helmut R. Mäcke et al.|Chemistry - A European Journal|1999|334

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation

Willem H. Bakker, Rainer Albert, Christian Bruns et al.|Life Sciences|1991|327